CAR T-cell therapy has emerged as a highly promising cancer treatment in recent years, with patient’s own cells being modified to aid their immune system to fight the disease. However, as explained here by Raul Cordoba, MD, PhD, of Fundacion Jimenez Diaz University Hospital, Madrid, Spain, CAR T-cell technologies are currently only being used fully in the USA. This means that European patients undergoing CAR T-cell therapy must wait for their cells to be sent to the USA, modified and then sent back, which can often be too long a wait for patients. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA.
CAR T-cell therapy in Europe: transporting cells to the USA
